I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem […]
Interview with Bioheart CSO, Kristin Comella including on FDA Read More »
By Jane Langille A few weeks ago, I wrote to Dr. Paul Knoepfler after reading his book Stem Cells: An Insider’s Guide because I was intrigued by his stem cell theory of aging. I wondered if his theory might mean that someone who mobilized and donated hematopoietic cells might be shortening their own lifetime supply. After
Risks for Healthy PBSC Donors? One Family’s Powerful Experience Read More »
In the last few months the FDA has taken steps toward crystalizing regulatory oversight of stem cell and more broadly cell and tissue-based therapies. These steps come in the form of several draft guidances (see here, here, and here) . The Alliance for Regenerative Medicine (ARM) has responded to the draft guidance on Minimal Manipulation. For example, ARM has
ARM Asks FDA for Clarification on Draft Guidance on Minimal Manipulation Read More »
One of my goals is promoting evidence-based medicine and science-based medicine that is in the best interest of the community including patients. Below is a list of recommended reading for you including mostly blogs, but also other resources that should be on your regular must-read list. Some are stem cell-focused, while most are broader. California
Recommended reading for innovative, evidence-based medicine Read More »
CIRM issued a press release (PR) a few days ago unveiling CIRM 2.0, a new form of the agency and funding of novel efforts. The PR focused on action by its Governing Board to fund three Alpha Clinic programs for $8 million each at City of Hope (LA), UCLA, and UCSD. The Alpha Clinics will
CIRM 2.0 Launches Alpha Clinics & Continues Bridges Program Read More »
Stem cell-based Regenerative Medicine has huge power for good in the clinic and at the same time great potential for economic development. Those two things go hand in hand. As I argued in my stem cell book, biotech commercialization of stem cells is not a bad thing, but rather if it is done responsibly it
Reflecting on Regenerative Medicine As A Brand Read More »
I did a brief email Q&A interview with Dr. Bob Lanza of Advanced Cell Technology (ACT) on their new hES MSCs pre-clinical data for Multiple Sclerosis. I discussed the paper itself in a concise review yesterday here. Thanks to Dr. Lanza for doing the interview. 1. Were you surprised at the fact that the therapeutic
Interview with Bob Lanza on new ACT MSCs for MS paper Read More »
The Alabama Institute of Medicine (AIM) is one of the great success stories in the stem cell research field. It’s an extraordinary achievement as a state stem cell agency. Below I’ve interviewed one of AIM’s founders and its Vice President, Tory Williams. Above you can see a picture of Tory with Roman Reed at the
Interview with Tory Williams of Amazing Alabama Institute of Medicine (AIM) Read More »
I just heard some very good news on the regenerative medicine front. US Senators Barbara Boxer and Mark Kirk today introduced The Regenerative Medicine Promotion Act, which would keep track of and promote regenerative medicine efforts. This is really exciting and provides hope. One of the neat things about this news is that Boxer is
Great News: Senators Boxer & Kirk Introduce Regen Med Bill Read More »
What does the future hold for CIRM? I asked former CIRM Board Chair and Prop 71 leader, Robert Klein, about that and more in the interview below. He also says some particularly exciting clinical trial and other developments in the stem cell field are coming soon. What got you excited for the very first time
Interview with Robert Klein on CIRM’s Future Read More »